What should I look for in IGF-1 LR3 sourcing and quality?

Acceptable IGF-1 LR3 certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 9111 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

Should I cycle IGF-1 LR3?

Standard cycle for IGF-1 LR3 is 8–12 weeks of 1-2x daily subq 20-50 mcg dosing via subq, followed by a 4 week complete off-period. The off-period is calibrated to IGF-1 LR3's ~20-30 hr (vs ~10 min for native IGF-1) half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

What is the mechanism of action of IGF-1 LR3?

Binds the IGF-1 receptor with full agonist activity. The N-terminal extension (LR3 — Long arginine-3) prevents binding to IGF-binding proteins, so circulating LR3 remains 'free' and bioactive. Drives anabolic signalling, muscle satellite cell activation, and hyperplasia of muscle fibers in animal models. For female hormonal and cyclical applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Binds the IGF-1 receptor with full agonist activity. The female physiology interpretation focuses on the pathway-level detail rather than on any single high-level summary.

Home/ Compounds/ IGF-1 LR3

IGF-1 LR3

Women's Health

Cycle-aware, fertility-aware, perimenopause-aware: IGF-1 LR3 is evaluated by women's-health clinicians on multiple axes. Binds the IGF-1 receptor with full agonist activity The N-terminal extension (LR3 — Long arginine-3) prevents binding to IGF-binding proteins, so circulating LR3 remains 'free' and bioactive. Drives anabolic signalling, muscle satellite cell activation, and hyperplasia of muscle fibers in animal models.. The compound's modified insulin-like growth factor 1 pharmacology produces measurable effects on the systems women's-health practice cares about — cycle regularity, mood, bone density, cardiovascular tone, and the perimenopausal transition. Each is examined in the sections below.

Female Physiology Applications

Autoimmune SupportPCOS SupportLibido (Female)Vaginal HealthMenopause

Key Takeaways

Female-physiology lens: IGF-1 LR3 response varies across follicular and luteal phases for premenopausal users; integrates with HRT in perimenopause and postmenopause.
Mechanism: Binds the IGF-1 receptor with full agonist activity.
Female monitoring: cycle-day-appropriate estradiol, progesterone, FSH, LH, prolactin, TSH, bone markers; pregnancy contraindication is default.
Female dose: 20-50 mcg 1-2x daily subq via subq; cycle-phase tracking for 1-2 cycles.
Female-physiology stack partners: Oxytocin, Kisspeptin, GHK-Cu.

Female Physiology Mechanism

Cyclical hormone background shapes how women experience IGF-1 LR3. Binds the IGF-1 receptor with full agonist activity. The N-terminal extension (LR3 — Long arginine-3) prevents binding to IGF-binding proteins, so circulating LR3 remains 'free' and bioactive. Drives anabolic signalling, muscle satellite cell activation, and hyperplasia of muscle fibers in animal models. For premenopausal users, phase-aware tracking across 1-2 cycles informs the schedule; for perimenopausal users, HRT integration is the dominant question; for postmenopausal users, bone density and cardiovascular tone become the priority considerations.

Fertility and reproductive considerations

IGF-1 LR3's effect on fertility-relevant endpoints — ovulation, ovarian reserve markers, uterine receptivity, lactation — deserves explicit consideration for women in the reproductive window. Most well-studied compounds have minimal direct effect on reproductive endpoints at therapeutic doses, but pregnancy and active conception remain explicit contraindications for most non-approved peptides.

Bone density and cardiovascular signalling

Two areas where female physiology diverges sharply post-menopause are bone remodelling and cardiovascular tone. IGF-1 LR3's effect on these systems is one of the underweighted but practically important considerations for women using peptides through the menopausal transition. Bone-marker labs (CTX, P1NP) and cardiovascular indices (lipids, blood pressure, hsCRP) provide a tractable monitoring framework.

Perimenopause and menopause integration

For women in the perimenopausal or post-menopausal window, IGF-1 LR3 is most effective when integrated with the broader hormonal picture — HRT (estrogen, progesterone, sometimes testosterone), bone-density support, and cardiometabolic monitoring. Many compounds in this category produce stronger effects in this window precisely because the surrounding hormonal landscape is changing.

Female Physiology Applications

Menopause

In the perimenopausal window, IGF-1 LR3 for menopause produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.

Cardiovascular (Female)

Cardiovascular (Female) is one of the dimensions on which women track IGF-1 LR3 response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.

Cycle Support

For cycle support in female users, IGF-1 LR3 is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.

Sleep

In the perimenopausal window, IGF-1 LR3 for sleep produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	20-50 mcg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	12-50 mcg	4–6 weeks initial cycle
Women's Health focus	SubQ	20-50 mcg	1-2x daily SubQ
Maintenance phase	SubQ	14-50 mcg	Ongoing with periodic pauses

Dose timing for IGF-1 LR3 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

IGF-1 LR3 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from women's-health clinicians.

IGF-1 LR3 + Oxytocin: Activates oxytocin receptors (OXTR) peripherally (uterine smooth muscle, mammary alveoli) and centrally (amygdala, hypothalamus, ventral tegmentum). Pairs naturally with IGF-1 LR3's mechanism in female physiology protocols.
IGF-1 LR3 + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with IGF-1 LR3's mechanism in female physiology protocols.
IGF-1 LR3 + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with IGF-1 LR3's mechanism in female physiology protocols.
IGF-1 LR3 + Epithalon: Identified by Khavinson in St. Pairs naturally with IGF-1 LR3's mechanism in female physiology protocols.

Safety & Regulatory Status

WADA: Banned (S2) FDA: Unapproved (research reagent) Research: Animal models; off-label use widespread

Hypoglycaemia risk (engages insulin receptor weakly). Site-specific muscle growth observed. Long-term human safety not established. Concerns regarding tumour growth in pre-existing malignancy.

Lens-specific safety considerations for female physiology use of IGF-1 LR3: Hypoglycaemia risk (engages insulin receptor weakly). Site-specific muscle growth observed. Long-term human safety not established. Concerns regarding tumour growth in pre-existing malignancy. Additional female physiology monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Long-R3 IGF-I — properties and uses

PMID 1429592

Supporting

IGF-1 LR3 muscle effects

PMID 10393945

IGF-1 LR3 vs Related Peptides

Compound	Profile	Onset	Best For
IGF-1 LR3	Modified insulin-like growth factor 1	~20-30 hr (vs ~10 min for native IGF-1)	Women's Health
Oxytocin	Posterior pituitary nonapeptide	~1-6 min plasma; CNS longer	The 'bonding hormone' — a posterior pituitary nonapeptide with effects on uterine contraction, lactation, and a wide range of social and sexual behaviour via central oxytocin receptors
Kisspeptin	Hypothalamic upstream regulator of GnRH	~28 min IV	The upstream master regulator of GnRH neurons — driving the entire HPG axis from above
PT-141	Melanocortin receptor agonist	~2-3 hr	An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women

Frequently Asked Questions

How will IGF-1 LR3 interact with my cycle?

For pre-menopausal users, response to IGF-1 LR3 often varies across follicular and luteal phases. The first 1–2 cycles should be used to track response by phase before settling on a fixed schedule. Even where the compound's pharmacology is not directly cyclical, metabolism and felt response shift across the cycle.

Best monitoring labs for female users?

Baseline panel: estradiol (cycle-day-appropriate), progesterone, FSH, LH, prolactin, TSH free T3 free T4, fasting glucose, HbA1c, lipids, CBC, CMP, hsCRP, vitamin D, ferritin. Follow-up at 6–8 weeks. For perimenopausal users add bone markers (CTX, P1NP) and cardiovascular indices.

Will IGF-1 LR3 affect contraceptive efficacy?

For most peptide compounds, contraceptive efficacy is not significantly affected. Compounds directly modulating the HPG axis (kisspeptin, gonadorelin) are exceptions and warrant alternative or additional contraceptive measures during use. IGF-1 LR3's specific interaction follows its mechanism.

Can I use IGF-1 LR3 alongside HRT?

Yes, in most cases. Integration with HRT — estrogen, progesterone, sometimes testosterone — is additive rather than competitive for most peptide compounds. Coordinating with a HRT-prescribing physician on dose timing and monitoring is the standard approach.

How does IGF-1 LR3's half-life affect dosing?

IGF-1 LR3 has a plasma half-life of ~20-30 hr (vs ~10 min for native IGF-1), which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under 1-2x daily subq dosing at 20-50 mcg per dose explains the typical onset timeline for female hormonal and cyclical endpoints.

What does IGF-1 LR3 stack well with?

For female physiology protocols, IGF-1 LR3 pairs with compounds on complementary pathways: Oxytocin, Kisspeptin, GHK-Cu. These pairings are selected because they engage independent receptor systems from IGF-1 LR3's primary mechanism (Binds the IGF-1 receptor with full agonist activity), producing additive or synergistic effects rather than receptor competition.

Clinical Protocol

Start a IGF-1 LR3 Protocol

Alukard provides physician-supervised women's health protocols with GMP-certified IGF-1 LR3 and Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get Protocol

Quick Facts

Molecular weight: 9111 Da
Sequence length: 83 aa
Half-life: ~20-30 hr (vs ~10 min for native IGF-1)
WADA: Banned (S2)
FDA: Unapproved (research reagent)
Research: Animal models; off-label use widespread

Stack Partners

Oxytocin

Kisspeptin

GHK-Cu

Epithalon

PT-141

Research Note

All female physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for IGF-1 LR3 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised women's health protocols

Start Your Female Physiology Protocol for IGF-1 LR3

Alukard provides physician-supervised women's health protocols with Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised